Finally Drugging The "Undruggable" RAS
After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.
The RAS- Targeted Drug Discovery Summit Europe is the only industry and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate.
With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.
Save €700 if you register by Friday 22 November. See all pricing and early booking discounts here.
Meet Our World-Class Speaker Faculty
Hear What Our 2019 Attendees Said
"The meeting content successfully captured the latest goings on in the field, and brought together all the key players in a setting that encouraged interaction."
James Aggen, Senior Director - Medicinal Chemistry, Revolution Medicines
“Cutting-edge science and transformative medicine presented and discussed in a stimulating environment."
Zhigang Weng, Director - Biology, Blueprint Medicines